N/A
Completed N=25
Natural Killer (NK) Cell Transplantation for AML
Source: ClinicalTrials.gov NCT00187096 ↗Enrolled (actual)
25
Serious AEs
12.0%
Results posted
Nov 2012
Primary outcomePrimary: Number of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant — 2; 3; 11 participants
Summary
The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant |
2; 3; 11 | — |
| PRIMARY Proportion of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant |
0.20; 1.00; 0.917 | — |
| SECONDARY Duration of Engraftment of Natural Killer (NK) Cells |
10 | — |
| SECONDARY Percent of Peak NK Cell Chimerism |
7 | — |
| SECONDARY Percent of Detectable Donor NK Cells at Day 28 |
29 | — |
| SECONDARY Day That Maximum NK Cell Engraftment Was Reached |
14 | — |
| SECONDARY Number of KIR-mismatched NK Cells |
210; 5,800 | — |
| SECONDARY Number of Participants With Evidence of NK Cells Lysing a Target Cell Line (K562) |
10; 0 | — |
| SECONDARY Relapse-free Survival |
100 | — |
| SECONDARY Overall Survival |
100; 0; 45.0 | — |
Eligibility Criteria
Inclusion Criteria
- Participants with AML that is in complete remission, is relapsed or refractory, or with increasing minimal residual disease.
- Participants in complete remission must have recovered from toxicity of previous therapy and have evidence of bone marrow recovery
- Participants who had prior stem cell transplant (SCT) must have no evidence of GVHD and 60 or more days have elapsed since the SCT.
Exclusion Criteria
- Participants who are pregnant
- Participants with inadequate renal, liver, or pulmonary functions
Data sourced from ClinicalTrials.gov (NCT00187096). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.